The Role of Belatacept‐Use and Senescence on Infectious and Mortality Complications After Kidney Transplantation
Careful selection of KT for belatacept-use is recommended in older recipients (≥ 55 years) due to the increased hazard of mortality, CMV, and EBV DNAemia.
Authors
- Karam M. Obeid (ORCID: https://orcid.org/0000-0002-4131-647X)
- Adam Bregman (ORCID: https://orcid.org/0009-0006-7337-5681)
- Wyatt Tarter
- Abdinoor Abdi
- Ben Langworthy
- Hareesh Singam
Institutions
- University of Minnesota (US)
- University of Wisconsin System (US)
- Cleveland Clinic (US)
- University of Wisconsin–Madison (US)
- University of Minnesota System (US)
- Medtronic (United States) (US)
- University of Minnesota Medical Center (US)
Publication Details
- Journal
- Transplant Infectious Disease
- Published
- 2026-01-26
- DOI
- https://doi.org/10.1111/tid.70175
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health